EL.En. S.p.A. (ELN) Earnings Call Transcript & Summary

November 16, 2020

Borsa Italiana IT Health Care Health Care Equipment and Supplies earnings 43 min

Earnings Call Speaker Segments

Operator

operator
#1

Welcome, everyone, to the conference call on EL.En.'s financial results for the third quarter of 2020. This call is being recorded, and it will also include a chance to ask questions at the end. Joining me are Andrea Cangioli, EL.En.'s Managing Director, and Enrico Romagnoli, EL.En.'s Chief Financial Officer and Investor Relations. Before we start, I'd like to point out that management will be making remarks on this call regarding future expectations, plans, and prospects, as well as forward-looking statements. Some statements on this call — including those that address the company's beliefs, plans, objectives, estimates, or expectations about possible future results or events — are forward-looking statements. Forward-looking statements carry known and unknown risks, among them general economic and business conditions and conditions in the industry where we operate and may be affected, should our assumptions prove inaccurate. As a result, no forward-looking statement can be guaranteed, and actual future results, performance, or achievements could differ materially from those expressed or implied by any such forward-looking statement. The company assumes no obligation regarding the content, nor to update the forward-looking statements to reflect events or circumstances that may arise after the date hereof. At this point, I'd like to hand the call over to Andrea Cangioli. Andrea, please go ahead.

Andrea Cangioli

executive
#2

Thanks, Bianca. And thanks to everyone for joining this call following the release of our third quarter financial report. As the figures indicate, and as you'll soon be seeing in detail, this quarter brought a strong recovery both in our sales volume and in our profitability. We had given you guidance about improvement we expected in revenue and profits during the second half of the year. Our financial results line up well with those expectations — in fact, they beat them on the revenue side, reaching a 5.2% decrease in revenue after nine months, which is better than the less than 10% we had guided for. EBIT and EBIT margin likewise improved during the period, producing a year-to-date EBIT margin of 6.8%, a marked increase over the 5.7% margin recorded in the first six months. The third quarter, typically the weakest one because of summertime and summer breaks, in this 2020 benefited from the positive effect that the summer months had on the spread of the pandemic, benefited from lighter restrictions, and from the optimism spreading among people. I recall that the first quarter was heavily affected by the Chinese lockdowns, and the second quarter by the lockdowns in Western countries.

Andrea Cangioli

executive
#3

To start with, Italy above all was where our operations had to be slowed, and in some businesses we stopped them entirely. Both revenue and profitability took a serious hit, notably in the industrial segment in Q1, at a time when the medical segment had not yet felt any impact from the pandemic, and then in the medical segment in Q2, when, conversely, we were already seeing a robust rebound, particularly in laser cutting activity within the industrial business. Step by step, restrictions came off across the globe. The business relationships we had built during the lockdown months with real determination — through constant, energetic remote marketing and outreach work — began paying off once more and steadily brought in a healthy flow of new orders. In the end, the restrictions amounted to limits on international travel and the cancellation of the majority of the trade fairs and congresses on our planned calendar. That did not stand in the way of the recovery we anticipated and that is visible today. In laser cutting, sales climbed back to record levels. In China, we are closing the gap with a market that advanced very rapidly and where our positioning in Wuhan and Guangzhou left us at a heavy disadvantage.

Andrea Cangioli

executive
#4

Revenues hit a record in the third quarter. Cutlite Penta also posted record sales in the Italian market, and Cutlite was among the few group entities to increase both sales and profits in 2020. As we've said, that sustained growth requires a substantial logistics effort so we can handle the growing count of large, heavy laser systems that we build. It's also worth noting that to strengthen our market share and position, we took a very aggressive commercial approach, which meant lower margins, particularly in China, where competition after lockdown looks stronger than it did previously. Another area with a significant rebound was the aesthetic segment of the medical sector. It seems that once the lockdown ended, demand for cosmetic treatments has been strong. In reaction to restrictions, people are keen to put part of their disposable income — which, in terms of net availability, is boosted by savings on travel and celebrations, to give one example — toward improving how they look. We also confirm that the long stretch of video calls drew attention to facial imperfections and increased the need for and demand for facial treatment. Broadly, this is how our markets are behaving.

Andrea Cangioli

executive
#5

From where we sit, the team performed really well in delivering products and procedures that could handle those kinds of needs and that level of demand. We feel proud and thankful for just how effective our R&D and engineering function proved during the period, which let a number of new systems reach the market. I want to highlight three new products now available for body treatments. Two of them rely on high-intensity magnetic field technology for muscle stimulation. Those new systems go by the name SCHWARZY for the medical market and B-Strong for the professional aesthetic market, and 1/3 rests on a mechanical micro-massaging technique, the system Icoone, which we build under license. Fresh technologies were also created for our surgical business, with Quanta System, among others, rounding out its product offering for urological surgery devices. All in all, we've witnessed a superb recovery in the laser cutting business, which right now is running at a faster pace than in 2019. Inside the medical sector, a particular segment of aesthetics beat 2019, specifically the Japanese market. Across all the remaining application segments and businesses, activity is recovering yet still running at a slower pace relative to 2019, with a gap in operation and sales pace that has been progressively narrowing. We're happy with our Q3 results, above all the outstanding sales volume, but with the profitability too, which, under the circumstances, was truly outstanding as well.

Andrea Cangioli

executive
#6

Margins on a gross basis dipped a little this period, and the main reason is that the two areas where we did better on revenues — laser cutting systems for sheet metal within the industrial business, plus medical system distribution across Japan — happen to be the very areas carrying thinner gross margins, which also slipped further during the period. Preserving the sales margin matters enormously, of course, yet there are times when growing sales or defending market share counts for more strategically. In every market we serve, we believe our competitive strength and position came out better this period. Our markets' growth potential over the coming years, we are confident, remains unchanged, and it will fall to us to seize that potential by equipping our sales and distribution network with a suitable range of innovative systems. Our confidence on this point is strengthened even further by the excellent operational standards present in all of our vital functions. Last, cash generation came in excellent, since operational cycles have returned to a smooth pattern following the abrupt disturbance we endured during the spring months.

Andrea Cangioli

executive
#7

Like everything else that has gone wrong in 2020, looking at how the business has trended over the past few months doesn't really give a good picture of what's coming next. During the last few weeks, the pandemic has been surging again, and multiple nations have gone back into lockdown. Germany made the announcement and began on November 1st. A few days afterward, France did the same. Last week Italy joined them, with a range of restriction levels that, unfortunately, are rapidly tightening toward the strictest ones. How fast the restriction situation shifts is illustrated by what took place in our region, Tuscany. Right here in Florence, within the span of a single week, we went from yellow — the milder restriction level — to red, which is presently the toughest of the restrictive levels in force in Italy. The good news: this new lockdown isn't as severe as the first. Production activities remain completely unaffected. The restrictions fall directly on restaurants, shops, and travel. As we shared in a recent communication, every one of our factories has put in place rigorous prevention measures and procedures that let our workers show up with confidence that they are protected in a safe workplace.

Andrea Cangioli

executive
#8

Also, a lot of them have gone back to working remotely so they can reduce the chance of contact. We are dealing with problems or cases where some employees or their family members have tested positive for COVID, but we adhere to rigorous protocols so that anyone who might be contagious is properly isolated in line with the regulations. The bad news is that some of our markets are being hit directly by restrictions. Aesthetic centers have had to shut down in Germany and in the Italian red zones. Visits to medical centers should be restricted to emergencies. This is already affecting our sales and will affect them over the coming months, particularly in the markets where we sell through distributors; as of today we see no change in the rather sizable backlog we have, which we intend to work off during the final weeks of the year. The same applies to the industrial market, where no sudden shift in demand is on the horizon. Naturally, our route back to normal would have been faster and simpler without this second round of restrictions. Before I return to the guidance, I would like to hand over to Enrico. He will walk you through the specifics of our quarterly financials. Thank you, Enrico.

Enrico Romagnoli

executive
#9

Thanks, Andrea. As usual, I'll share a few specifics about our most recent financials. The first nine months of 2020 ended with consolidated turnover of EUR 260 million, a decline of 5.2% versus the same period last year, together with a strong rebound in the third quarter of 11.8%, which trimmed the 13.8% drop seen in the first six months. As Andrea already noted, the results are heavily affected by the impact the COVID pandemic had on our business and our markets, primarily during the first six months. On gross margin, it came in at EUR 194.4 million, 15% lower than the EUR 111.1 million recorded on September 2019, reflecting the decline in turnover and a margin reduction that the crisis brought about in both sectors, medical and industrial, with a sharper effect in the industrial sector for the cutting laser system, where the return to high production and sales volumes was accompanied by stronger competitive pressure. Partly in the medical sector, this was due to the notable growth in sales volume of certain aesthetic devices sold as accessories to the laser system made by the group and mostly sold in the Japanese market, carrying a margin below the sector average.

Enrico Romagnoli

executive
#10

Operating costs came in at EUR 24 million, lower than the EUR 31 million recorded on September 2019, and their weight on turnover fell from 11% to 8.9%. Those savings come chiefly from restricted travel and from calling off every fair and congress event, along with lower activity volumes. Staff cost for September 2020 stood at EUR 44.7 million versus EUR 47.5 million a year earlier. The drop in labor cost stems mainly from government payroll protection schemes like Cassa Integrazione in Italy, which was also used in France and Germany, plus a decrease in staff overtime. As of September, the group employed more than 1,600 people, and new hires were concentrated in China, where the factory is running at full capacity with volume above last year's level. EBITDA reached EUR 25.8 million, a decline of 21% from the EUR 33.6 million posted in the nine months of last year, with a margin on sales of 9.6% against 11.5%. Amortization and other accruals rose by EUR 1.5 million, reflecting the significant investment made in 2019 and a higher provision for bad debt, so as to reflect in the most balanced way the possible deterioration of certain credit positions.

Enrico Romagnoli

executive
#11

During the first nine months of 2020, bad debt rose by EUR 0.9 million. Across that same nine-month span, the combined total of fixed costs, operating costs, staff costs, and depreciation declined by 10%, a steeper drop than the fall in sales. Sales were affected by 28%, versus 30% a year earlier. Because the burden of fixed costs on sales was lowered, the 4% hit to profitability at the gross margin level shrank to 2.5% at the EBIT level, which came in at a positive EUR 15.1 million, down from EUR 26.4 million, with an impact on sales of 6.8% against 9.3%. Pretax result stood at EUR 16.9 million, weighed down by a negative Forex effect and a negative contribution from associated companies. For Q3, the same explanation applied to the nine months accounts for the decline in gross margin profitability. At the same time, profitability recovered, with an EBIT margin of 8.4% — below Q3 of 2019, yet the strongest result posted in the first three quarters of 2020. Q3 also saw a huge Forex impact that brought income before taxes down to EUR 7.9 million.

Enrico Romagnoli

executive
#12

Our net financial position showed a positive balance of EUR 49.8 million, which is lower than the EUR 61.4 million we had last year, and it includes EUR 27.9 million from the first half. Roughly EUR 20 million in cash went toward acquiring an important minority stake in Penta Laser Wenzhou in China, and growth in net working capital absorbed about EUR 9.6 million of liquidity, largely because inventories rose in value. Investment in technical fixed assets came to approximately EUR 9.6 million, below last year's figure. Cash generation in the quarter was strong at more than EUR 20 million, helped by a solid level of activity and a decrease in net working capital. Within the medical sector, the 6.4% decline is somewhat more pronounced in system sales than in the other sales services and consumables, which posted stable revenues for optical fibers for urological surgery. The stability of the aesthetic sector is extraordinary. There are two main reasons for this result. The first is the market launch of the new system for hair removal, body shaping, and skin treatment, which carries a high degree of innovation and has met with great success in the market.

Enrico Romagnoli

executive
#13

Next, our Japanese branch performed well, thanks to upgrades within the installed base and to sales of a meaningful volume of equipment made locally through those same channels. By contrast, sales in surgery — and even more noticeably in physiotherapy — were hit by the COVID pandemic, since the focus of healthcare facilities was chiefly on treating COVID-related problems. Following a robust rebound in Q2, the industrial sector's recovery carried on with an exceptional third quarter, posting growth of 28.8% versus the third quarter of last year. In the cutting segment, which over the recent year has grown into the most important one for the group, turnover recovered steadily, rising 2.4% compared with last year, while the gain in the quarter was exceptional at +43%. Our other three main segments — marking laser sources and after-sales service — keep feeling the pandemic's effects. After nine months, they showed a double-digit decline, with no meaningful improvement during the quarter. Turning to how revenue is distributed across geographical areas, within industrial, the solid results in the Italian and European markets stemmed from growth in the metal cutting system.

Enrico Romagnoli

executive
#14

Outside Italy, a 10% decline came from the inventory situation that hit our Chinese operations during Q1, though that shortfall is narrowing versus the first six months. Where medical is concerned, demand fell broadly across both European and extra-European markets, yet outside Europe we held steady, helped by solid results in Japan and by the US market's resilience. Italy felt the impact severely when medical and professional beauty activity froze, producing a 37% contraction in the first half; then Q3 brought a strong 28% rebound, which trimmed the year-on-year drop to 21%. Andrea, over to you.

Andrea Cangioli

executive
#15

So, just to wrap up our presentation—thanks, Enrico. Let me return to the guidance. As I said earlier, we're on the right track. We're getting back to the growth and profitability rates we had planned. If this call had happened two weeks ago, we'd have been discussing raising the guidance upward, in recognition of the third quarter results and the momentum we have. But with the recent pandemic developments and the restrictive limitations being enforced again around the world, we're entering a phase of greater uncertainty. Confident and hopeful that the coming weeks—the next weeks—will confirm that these restrictions aren't changing the overall trend of our demand, we're able today to confirm the current guidance as released in September, which is to improve profitability in the second half of the year and to limit to 10% the yearly sales shortfall of 2020 versus 2019. At this point, we've finished our presentation. We're opening the call to your questions. Please go ahead.

Operator

operator
#16

We're ready to begin the question-and-answer portion now, and please do state who you are before posing your question — thank you.

François Robillard

analyst
#17

Hello there. This is François Robillard calling from Intermonte. Are you able to hear me?

Andrea Cangioli

executive
#18

Yes.

Enrico Romagnoli

executive
#19

Yes.

François Robillard

analyst
#20

Hello there, and good afternoon to all of you. I appreciate you taking my question, and I trust everyone is doing well. My first one concerns medical aesthetics. Performance last quarter was pretty good. I'm just curious to learn what portion of that rebound stemmed from the backlog of orders left over from the closures in the second quarter, and what portion came from the new products. A related question: could you update us on how sales of your new products have been performing? I have SCHWARZY in mind, along with all the other innovative products you showed us following the second quarter results. Could you give us a sense of the gross margins for both segments in the third quarter? You mentioned that competitive pressure in China is affecting your industrial segment gross margins quite a lot. Could you just give us a sense of the consolidated gross margin levels for industrial and for medical in the third quarter? On the last question, a bit of a trading update. You said Japan and the U.S. performed pretty well in the third quarter. I assume that lockdown restrictions in those geographies lately have also been less restrictive than those in Europe.

François Robillard

analyst
#21

Is it fair to say you remain fairly optimistic about those regions for Q4? That’s all. Thanks a lot.

Andrea Cangioli

executive
#22

Thanks, François. Now, turning to orders: in medical aesthetics, the backlog at the close of September exceeded the one we had at the end of March. That tells us that over this quarter we've been shipping against orders booked earlier, while also bringing in a really solid order volume. As I said on the call, things kept improving progressively as the quarter wrapped up, and in October we were steadily doing better, moving nearer to the pace we enjoyed back in 2019. On gross margin, as I described in a way during the call and in my presentation, gross margin came down in both medical and industrial. Overall we're at 35.2%. Medical gross margin stood at roughly 42%. Industrial gross margin was roughly 25%. What I want to flag on that front is that medical gross margin fell in the third quarter because we had a batch of very large sales in Japan, where we act as distributor, and that business carried a comparatively thin margin. That pulled down the margin on the Japan sales and pulled down the margin across medical sector sales overall. The situation in Japan has been extremely positive.

Andrea Cangioli

executive
#23

Two businesses managed to grow both revenue and profits in 2020 compared with 2019. One of them operates in industrial laser cutting systems. The other one sits right here with us — that's our Japanese distribution. Lockdowns did happen in Japan, though they weren't as strict as those seen in Italy or across Europe. On top of that, news released today shows the Japanese economy rebounding very, very strongly. The pandemic is reappearing in Japan as well, but even so, it appears far better contained than in our Western countries. That's why we anticipate solid business levels in Japan through this final stretch of the year. The same applies to the United States, where we're performing quite well, particularly in aesthetics. Very much in aesthetics and in surgery. Let me add something on this. Our key customers on U.S. soil — Cynosure, for whom we sell an OEM-based hair removal system that should really take off over the coming months, and Cartessa, the distributor of DEKA-branded and Quanta System branded devices for the United States — are both doing very well. Naturally, we can't predict whether the Biden administration will take a different approach to combating the pandemic, and that would affect our margins.

Andrea Cangioli

executive
#24

At the moment, a substantial share of the improvement in our order books comes from very strong performance in the U.S. market. One thing I should have brought up sooner, which I didn't cover in my presentation, is that in aesthetic we're seeing a strong inclination toward spending more on appearance and directing disposable income to aesthetics during this post-lockdown period. In surgery, demand is still weak at this point, since every hospital structure and every national health structure is intensely focused on combating COVID and on arranging its structures for COVID. Every investment and all of the attention goes to COVID, and it's more difficult right now to carry out any commercial activity with structures that, as I said, are intensely concentrated on the pandemic. I believe I've addressed the three questions.

Analyst

analyst
#25

Andrea, if I could just ask something — Bianca, would that be all right?

Operator

operator
#26

Yes, absolutely.

Analyst

analyst
#27

Hello, everyone. My question is about gross margin once more. We're aware that competition is extremely fierce in China within industrial laser. Could you give us an update on what you're doing to lower the breakeven point in China or to enhance profitability? In the past you referenced certain specific measures. If you could summarize where things stand regarding the actions in China in industrial laser. The second one is more specific about the guidance. You're maintaining your guidance, but it implies a quite sharp decline in the final quarter of the year, even with a solid October. Do you anticipate a very significant slowdown during the last couple of months of the year purely because of European lockdowns? That's my last question. Thank you, Andrea.

Andrea Cangioli

executive
#28

Let me begin with the second question. No—we just sense a lot of uncertainty right now. As of today, the one thing we can state with certainty is that we won't be able to deliver almost anything in Italy to cosmetic centers located in the red areas, which currently cover most of the country. We know the same will be true for Germany during this period, so the impact is limited. Beyond that, we expect the trend we saw in the third quarter to carry on. In fact, what we've done is not to say that our revenue will fall or that our trend will be declining—rather, given the turmoil underway, we lack the confidence to assume we can consistently improve. I don't think we'll have a bad fourth quarter. We're simply not as confident as we were 20 days ago that we can improve further. That's the point. On gross margin and the industrial laser business, there are three aspects I'd like to highlight here. First, in the business segment in Italy, we're being very aggressive, and we're lowering gross margin to gain market share, which is vital for a business that was very small and that is looking to reach the EUR 50 million milestone in 2020.

Andrea Cangioli

executive
#29

Our approach is an aggressive one when it comes to expansion, aimed at taking up spaces where our competitors weren't quick enough to move in. When it comes to China, the margin reduction stems partly from that same strategy and partly from intense competitive pressure. A redesign process is underway that will let us save a few hundreds of thousands of renminbi per system, and it is already delivering some cost savings in Q4 2020, just as we had, let's say, promised or forecasted. This morning I discussed this situation with my management in China — it's one of the focal points for them as they manage through this end of the year — and demand this month in China remains very strong, since China, as you know, is basically unaffected by COVID at this moment. We anticipate strong demand, and we also anticipate recovering a few decimal points, hopefully a few points, of gross margin thanks to this effort, which, as mentioned, is a technical one. I was also reviewing the monthly sales reports for October. Another piece of good news on our side is that overseas sales are growing once more, which means a more significant share of our sales will come from outside China, and those sales carry a higher margin.

Andrea Cangioli

executive
#30

It will also let us boost performance. There's one more point I want to raise regarding China. On December 12th, the grand opening takes place for our second factory and offices in Wenzhou. Customers from across all of China will be flying in for this event. Beyond the fact that we now have an additional facility — already structured, well prepared, and operational — it will be officially inaugurated that day, which supports growing our sales volume. We also anticipate a highly significant commercial impact from this event, and we expect hundreds of customers to gather in Wenzhou for it.

Analyst

analyst
#31

Thanks a lot, Andrea.

Andrea Cangioli

executive
#32

Glad to have you with us.

Operator

operator
#33

Are there any other questions?

François Robillard

analyst
#34

And if I could ask one more, assuming no one else is waiting. It’s François Robillard with Intermonte once more.

Andrea Cangioli

executive
#35

Absolutely.

Operator

operator
#36

Alright.

François Robillard

analyst
#37

Yeah, just one quick thing. If I remember right, you used some government-backed loans or guarantees in Italy. Is that going to affect your ability to pay out some dividends next year?

Andrea Cangioli

executive
#38

That's a good question. I don't think the company would keep paying dividends if conditions stay the way they look today. The reason we didn't pay a dividend was so we wouldn't limit our ability to seek government funding in the event of a disaster. As of today, no disaster has occurred. Hopefully, by the time dividend decision season comes around again — so early spring — we'll have a clearer picture of whether a disaster has happened or not. Right now we don't see a disaster, and so right now, I don't see any reason we wouldn't be able to pay a dividend in 2020. On government support, that's a hot topic for us, because we're having trouble working out whether certain government support we've received must be counted within a limit of EUR 800,000 for each company. Okay. I'd say we're struggling with the government support in Italy, which at first looked like they were supporting EUR 800,000 per company under a certain rule called de minimis. Now it looks like they're backing up to EUR 800,000 for the group, which is a material difference.

Andrea Cangioli

executive
#39

Putting dividends aside entirely — none of this relates to them. I want to state clearly that, provided our financial position permits it, and nothing at present leads us to think that won't be the case, we will in all likelihood go back to making regular dividend payments in 2021.

François Robillard

analyst
#40

All right, thanks. Do you figure you'll be drawing on Cassa Integrazione once more in Q4?

Andrea Cangioli

executive
#41

Right now, we have not been making use of Cassa Integrazione. We do use it in France, since we have a distribution company there that is unable to distribute at present, or whose distribution is very limited. We may be compelled to resort to Cassa Integrazione for the company Esthelogue, which operates in professional aesthetic distribution in Italy, because the market at present is extremely limited. We cannot sell any devices in places where the cosmetic centers are closed, and that covers all the red areas. For all the remaining business, we are operating as usual. As of today, we do not foresee any need to return to Cassa Integrazione.

François Robillard

analyst
#42

I appreciate that.

Andrea Cangioli

executive
#43

Right now, we're in a situation where the current status isn't bad. Production is also running at full capacity here in Florence. There's a lot of uncertainty. We hope things stay the same, and then we'll be wrapping up a very good year. These events, which are entirely outside our control, could affect our financial results between now and the end of the year. Unfortunately, we have no control over that whatsoever. We're confident because we have a very strong order backlog, and if we're permitted to keep working, I believe the results will come.

Operator

operator
#44

Is there anything else anyone would like to ask?

Andrea Cangioli

executive
#45

All right. It seems everyone is satisfied with what they've heard so far. That's all the questions we have.

Operator

operator
#46

Are there any further questions from investors? Hearing none, we'll bring this conference to a close. We appreciate your participation and look forward to having all of you with us next time. Good afternoon, everyone. Bye. Thank you.

Enrico Romagnoli

executive
#47

Thanks. Goodbye.

Andrea Cangioli

executive
#48

Take care.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete EL.En. S.p.A. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to EL.En. S.p.A. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in EL.En. S.p.A. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.